Publicaciones en colaboración con investigadores/as de University of Western Australia (9)

2023

  1. Zanubrutinib Versus Ibrutinib in Symptomatic Waldenström Macroglobulinemia: Final Analysis From the Randomized Phase III ASPEN Study

    Journal of clinical oncology : official journal of the American Society of Clinical Oncology, Vol. 41, Núm. 33, pp. 5099-5106

2022

  1. IBCL-117 ASPEN: Long-Term Follow-Up Results of a Phase 3 Randomized Trial of Zanubrutinib vs Ibrutinib in Patients With Waldenström Macroglobulinemia

    Clinical Lymphoma, Myeloma and Leukemia, Vol. 22, pp. S385

  2. Pooled safety analysis of zanubrutinib monotherapy in patients with B-cell malignancies

    Blood Advances

2020

  1. A randomized phase 3 trial of zanubrutinib vs ibrutinib in symptomatic Waldenström macroglobulinemia: The ASPEN study

    Blood, Vol. 136, Núm. 18, pp. 2038-2050

  2. Zanubrutinib for the treatment of MYD88 wild-type Waldenström macroglobulinemia: A substudy of the phase 3 ASPEN trial

    Blood Advances, Vol. 4, Núm. 23, pp. 6009-6018

2018

  1. How immunological profile drives clinical phenotype of primary Sjögren's syndrome at diagnosis: Analysis of 10,500 patients (Sjögren Big Data Project)

    Clinical and Experimental Rheumatology, Vol. 36, pp. S102-S111

2016

  1. An international, multicenter, prospective, observational study of neutropenia in patients being treated with lenalidomide + dexamethasone for relapsed or relapsed/refractory multiple myeloma (RR-MM)

    American Journal of Hematology, Vol. 91, Núm. 8, pp. 806-811

2013

  1. Common susceptibility alleles and SQSTM1 mutations predict disease extent and severity in a multinational study of patients with Paget's disease

    Journal of Bone and Mineral Research, Vol. 28, Núm. 11, pp. 2338-2346

2010

  1. Quality, quantity and harmony: The DataSHaPER approach to integrating data across bioclinical studies

    International Journal of Epidemiology, Vol. 39, Núm. 5, pp. 1383-1393